Evidence map›Paper›PMID 20504921›Full record

ArticleJournal of virology2010

Impaired replication capacity of acute/early viruses in persons who become HIV controllers.

Toshiyuki Miura, Zabrina L Brumme, Mark A Brockman, Pamela Rosato, Jennifer Sela, Chanson J Brumme, Florencia Pereyra, Daniel E Kaufmann, Alicja Trocha, Brian L Block and 11 more

Abstract read
In one paragraph

Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 141 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. HIV controllers, lessons learnt from the lymphoid tissues.Current opinion in HIV and AIDS · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. CD8Nature reviews. Immunology · 2020
    Review
  17. Article
  18. Article
  19. The phylogenomics of evolving virus virulence.Nature reviews. Genetics · 2018
    Review
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 4 countries.

Toshiyuki MiuraRagon Institute of MGH, MIT and Harvard, Boston, Massachusetts, USA. miura523@ims.u-tokyo.ac.jp
Zabrina L Brumme
Mark A Brockman
Pamela Rosato
Jennifer Sela
Chanson J Brumme
Florencia Pereyra
Daniel E Kaufmann
Alicja Trocha
Brian L Block
Eric S Daar
Elizabeth Connick
Heiko Jessen
Anthony D Kelleher
Eric Rosenberg
Martin Markowitz
Kim Schafer
Florin Vaida
Aikichi Iwamoto
Susan Little
Bruce D Walker
Ragon Institute of MGH, MIT and Harvard · USUniversity of California, San Diego · USAIDS United · USAIDS Vancouver · CAHoward Hughes Medical Institute · USJohns Hopkins University Center for AIDS ResearchRockefeller University · USThe Lundquist Institute · USThe University of Tokyo · JPUniversity of Colorado Denver · USUNSW Sydney · AU

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI Daniel Lingwood · 2004 to 2026
$94.4M
Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
VIRAL AND IMMUNE CONSEQUENCES OF EARLY HIV1 THERAPYU01AI041534 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI MARKOWITZ, MARTIN H · 1997 to 2006
$10.1M
Immunopathogenesis of Acute HIV-1 InfectionP01AI055356 · NIAID · UNIVERSITY OF COLORADO DENVER · PI CONNICK, ELIZABETH · 2003 to 2007
$9.1M
TRANSMISSION AND VIRAL DYMANICS OF DRUG RESISTANT HIV-1R01AI047033 · NIAID · AARON DIAMOND AIDS RESEARCH CENTER · PI MARKOWITZ, MARTIN H · 2000 to 2011
$6.0M
INHIBITION OF HIV1 REPLICATION BY CYTOTOXIC LYMPHOCYTESR01AI030914 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 1991 to 2013
$4.2M
Immunoregulatory networks and HIV pathogenesisR01HL092565 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KAUFMANN, DANIEL E · 2007 to 2015
$3.4M
HIV-1-SPECIFIC T CELL CLONESR01AI028568 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 1989 to 2008
$1.9M
HIV-1 SPECIFIC T CELL CLONESR37AI028568 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 1994 to 2003
$1.6M
CIHRHoward Hughes Medical InstituteNHLBI NIH HHS R01 HL092565NIAID NIH HHS AI028568NIAID NIH HHS AI030914NIAID NIH HHS AI041534NIAID NIH HHS AI047033NIAID NIH HHS AI55356NIAID NIH HHS P01 AI055356NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI028568NIAID NIH HHS R01 AI030914NIAID NIH HHS R01 AI047033NIAID NIH HHS R24 AI106039NIAID NIH HHS R37 AI028568NIAID NIH HHS U01 AI041534
6 · The paper itself

Abstract

Human immunodeficiency virus type 1 (HIV-1) controllers maintain viremia at <2,000 RNA copies/ml without antiretroviral therapy. Viruses from controllers with chronic infection were shown to exhibit impaired replication capacities, in part associated with escape mutations from cytotoxic-T-lymphocyte (CTL) responses. In contrast, little is known about viruses during acute/early infection in individuals who subsequently become HIV controllers. Here, we examine the viral replication capacities, HLA types, and virus sequences from 18 HIV-1 controllers identified during primary infection. gag-protease chimeric viruses constructed using the earliest postinfection samples displayed significantly lower replication capacities than isolates from persons who failed to control viremia (P = 0.0003). Protective HLA class I alleles were not enriched in these early HIV controllers, but viral sequencing revealed a significantly higher prevalence of drug resistance mutations associated with impaired viral fitness in controllers than in noncontrollers (6/15 [40.0%] versus 10/80 [12.5%], P = 0.018). Moreover, of two HLA-B57-positive (B57(+)) controllers identified, both harbored, at the earliest time point tested, signature escape mutations within Gag that likewise impair viral replication capacity. Only five controllers did not express "protective" alleles or harbor viruses with drug resistance mutations; intriguingly, two of them displayed typical B57 signature mutations (T242N), suggesting the acquisition of attenuated viruses from B57(+) donors. These data indicate that acute/early stage viruses from persons who become controllers have evidence of reduced replication capacity during the initial stages of infection which is likely associated with transmitted or acquired CTL escape mutations or transmitted drug resistance mutations. These data suggest that viral dynamics during acute infection have a major impact on HIV disease outcome.

Indexed as

HIV Long-Term SurvivorsVirus ReplicationDrug Resistance, ViralHistocompatibility Antigens Class IHIV-1HIV InfectionsHumansMolecular Sequence DataMutation, MissenseRNA, ViralSequence Analysis, DNAT-Lymphocytes, CytotoxicViral LoadViremiaHistocompatibility Antigens Class IRNA, Viral

Identifiers

PMID20504921
PMCPMC2897600
OpenAlexW2161020185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.